Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wedbush

Wedbush downgraded shares of Keros Therapeutics (NASDAQ:KROS - Free Report) from an outperform rating to a neutral rating in a research report sent to investors on Friday morning, MarketBeat Ratings reports. Wedbush currently has $15.00 price target on the stock, down from their previous price target of $47.00.

Several other equities analysts also recently issued reports on KROS. Scotiabank reduced their price target on shares of Keros Therapeutics from $44.00 to $41.00 and set a "sector outperform" rating for the company in a report on Thursday. TD Cowen downgraded Keros Therapeutics from a "buy" rating to a "hold" rating in a research report on Thursday, December 12th. Jefferies Financial Group started coverage on Keros Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating on the stock. HC Wainwright decreased their price target on Keros Therapeutics from $100.00 to $47.00 and set a "buy" rating for the company in a research note on Friday, December 13th. Finally, Truist Financial reduced their price objective on shares of Keros Therapeutics from $100.00 to $43.00 and set a "buy" rating for the company in a report on Monday, December 23rd. Five analysts have rated the stock with a hold rating and nine have given a buy rating to the company's stock. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $52.56.

Keros Therapeutics Stock Up 3.2 %

Shares of NASDAQ:KROS traded up $0.34 on Friday, reaching $10.86. 2,986,409 shares of the company's stock were exchanged, compared to its average volume of 1,205,141. The business's 50-day moving average is $36.37 and its two-hundred day moving average is $47.13. Keros Therapeutics has a fifty-two week low of $9.77 and a fifty-two week high of $73.00. The firm has a market capitalization of $439.94 million, a price-to-earnings ratio of -2.08 and a beta of 1.43.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last issued its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million during the quarter. Keros Therapeutics had a negative return on equity of 41.74% and a negative net margin of 27,890.94%. The firm's revenue was up 4750.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($1.33) earnings per share. Analysts predict that Keros Therapeutics will post -4.74 earnings per share for the current fiscal year.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its stake in shares of Keros Therapeutics by 3.8% during the 3rd quarter. FMR LLC now owns 4,899,134 shares of the company's stock worth $284,493,000 after purchasing an additional 179,374 shares in the last quarter. Alkeon Capital Management LLC raised its position in Keros Therapeutics by 18.7% during the third quarter. Alkeon Capital Management LLC now owns 1,897,601 shares of the company's stock valued at $110,194,000 after acquiring an additional 298,694 shares in the last quarter. Darwin Global Management Ltd. lifted its stake in Keros Therapeutics by 6.3% in the second quarter. Darwin Global Management Ltd. now owns 1,525,902 shares of the company's stock valued at $68,772,000 after acquiring an additional 89,952 shares during the last quarter. Point72 Asset Management L.P. lifted its position in shares of Keros Therapeutics by 155.9% in the third quarter. Point72 Asset Management L.P. now owns 947,570 shares of the company's stock worth $55,025,000 after buying an additional 577,220 shares during the last quarter. Finally, Holocene Advisors LP increased its holdings in shares of Keros Therapeutics by 22.5% during the 3rd quarter. Holocene Advisors LP now owns 843,110 shares of the company's stock worth $48,959,000 after purchasing an additional 154,784 shares during the period. Institutional investors and hedge funds own 71.56% of the company's stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.